CG Oncology (NASDAQ:CGON) & Valneva (NASDAQ:VALN) Head to Head Survey

Valneva (NASDAQ:VALN) and CG Oncology (NASDAQ:CGON) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, analyst recommendations and valuation.

Earnings and Valuation

This table compares Valneva and CG Oncology”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Valneva	$158.54 million	3.77	-$109.78 million	($0.13)	-56.62
CG Oncology	$684,000.00	2,789.17	-$48.61 million	N/A	N/A

CG Oncology has lower revenue, but higher earnings than Valneva.

Institutional & Insider Ownership

11.4% of Valneva shares are owned by institutional investors. Comparatively, 26.6% of CG Oncology shares are owned by institutional investors. 14.9% of Valneva shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Valneva and CG Oncology’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Valneva	-4.35%	-3.93%	-1.42%
CG Oncology	-10,642.98%	-18.97%	-15.36%

Analyst Recommendations

This is a summary of current ratings and target prices for Valneva and CG Oncology, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Valneva	0	0	2	0	3.00
CG Oncology	0	0	8	1	3.11

Valneva currently has a consensus target price of $17.00, suggesting a potential upside of 130.98%. CG Oncology has a consensus target price of $65.14, suggesting a potential upside of 159.64%. Given CG Oncology’s stronger consensus rating and higher probable upside, analysts clearly believe CG Oncology is more favorable than Valneva.

Summary

CG Oncology beats Valneva on 7 of the 12 factors compared between the two stocks.

About Valneva

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France.

About CG Oncology

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.